Supraventricular Tachycardia (SVT) Management

Introduction to SVT Management

• Supraventricular tachycardia (SVT) is a condition that requires prompt management, with treatment guidelines provided by the American Heart Association and the American College of Cardiology 1, 2, 3, 4

Treatment Guidelines

• For adult patients with SVT, the American Heart Association recommends administering verapamil 2.5-5 mg IV bolus over 2 minutes (over 3 minutes in older patients), with repeated doses of 5-10 mg every 15-30 minutes to a maximum total dose of 20 mg if initial response is inadequate 1
• Verapamil should be administered under continuous ECG and blood pressure monitoring, and the medication is contraindicated in patients with wide-complex tachycardias, impaired ventricular function, heart failure, pre-excited atrial fibrillation or flutter 1
• The American Heart Association advises against using verapamil in combination with other AV nodal blocking agents with longer half-lives, as it can cause profound bradycardia, and to be prepared for potential hypotension 1
• Adenosine is a first-line pharmacological agent for SVT, with a success rate of approximately 91-95%, and should be used with caution in severe asthma, and may require higher doses in patients on theophylline, with effects potentiated by dipyridamole, and may produce VF in patients with coronary artery disease 5, 6, 4
• The initial dose of adenosine is 6 mg IV rapid push through a large vein followed by 20 mL saline flush, as recommended by the American Heart Association 1
• Non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, are recommended with a Class I, Level B-R recommendation for the treatment of SVT 3
• Alternative beta-blockers, such as metoprolol and atenolol, can be considered, with a therapeutic dose range of 25-200 mg twice daily for metoprolol 2
• Dihydropyridine CCBs (including nifedipine) should be avoided for SVT treatment due to potential harm, with a Class III: Harm, Level of Evidence: B recommendation 7, 3

Stepwise Approach for Treating Narrow Complex Tachycardia

• The stepwise approach for treating narrow complex tachycardia is recommended by the American College of Cardiology, starting with vagal maneuvers (success rate: approximately 27.7%), followed by adenosine (success rate: approximately 95% in AVNRT and 91% in PSVT), then calcium channel blockers or beta blockers, and finally synchronized cardioversion (highly effective) 2, 3, 4
• The following table summarizes the stepwise approach for treating narrow complex tachycardia:

2, 3, 4

Special Considerations

• In older children (not infants), the dose of verapamil is 0.1-0.3 mg/kg IV bolus over at least 2 minutes (usual range: 2-5 mg) 8
• Vagal maneuvers and adenosine are the preferred initial therapeutic choices for the termination of stable PSVT, followed by calcium channel blockers or beta-blockers if initial treatments fail, with synchronized cardioversion reserved for hemodynamically unstable patients or refractory cases, as recommended by the American Heart Association 1
• Synchronized cardioversion is indicated for hemodynamically unstable patients or when pharmacological therapy fails, with an initial biphasic energy of 50-100 J for SVT, and energy increased in a stepwise fashion if unsuccessful, as recommended by the American Heart Association 1
• Synchronized cardioversion is highly effective in terminating SVT, with a Class I, Level B-NR recommendation 2, 9, 10, 4, 3

Long-term Management

• Oral beta blockers, diltiazem, or verapamil are recommended as first-line therapy for long-term management of PSVT, with a Class I, Level B-R recommendation 4
• Flecainide or propafenone are recommended as second-line options for long-term management of PSVT, with a Class IIa, Level B-R recommendation, and are reasonable for patients without structural heart disease, but should be avoided in patients with structural heart disease or ventricular dysfunction due to increased risk of proarrhythmia 4, 3

Patient Education and Follow-up

• Patients should be taught proper vagal maneuver techniques for home use, and warned about the signs and symptoms that require medical attention 3
• For infrequent, well-tolerated episodes, a "pill-in-the-pocket" approach may be considered, with oral beta blockers, diltiazem, or verapamil 3
• Refer patients to cardiology or electrophysiology within 1-2 weeks after initial presentation, and consider catheter ablation as definitive treatment, with success rates of 94-98%, and provides a potential cure without the need for chronic medications, with a Class I, Level B-NR recommendation 2, 4, 3, 11

Considerations in Specific Populations

• In pregnancy, adenosine is safe due to its short half-life, and the lowest recommended medication doses should be used, with avoidance of medications in the first trimester if possible 4, 3, 2
• In end-stage renal disease, monitoring for electrolyte abnormalities and awareness of dialysis-related fluid shifts triggering arrhythmias is important 4, 3